Patents by Inventor Charles E. DiLiberti

Charles E. DiLiberti has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of reducing symptoms in subjects using single dosage forms with tapering release rates
    Patent number: 9220692
    Abstract: The present invention is directed to methods of reducing symptoms associated with an abrupt reduction in an endogenous or exogenous chemical in subjects, the methods comprising: (a) administering to the subject a single dosage form comprising an active agent, wherein the release rate of the active agent from the single dosage form tapers throughout the administration; and (b) removing the single dosage form from the subjects after the release rate of the active agent is at or below a terminal symptom threshold level.
    Type: Grant
    Filed: May 5, 2011
    Date of Patent: December 29, 2015
    Assignee: TEVA WOMEN'S HEALTH, INC.
    Inventors: Charles E. DiLiberti, Anu Mahashabde
  • Oral dosage forms comprising progesterone and methods of making and using the same
    Patent number: 8663681
    Abstract: The present invention relates to an oral pharmaceutical dosage form comprising micronized progesterone, an edible oil, a disintegrant, and a hydrophilic excipient. Particularly, the invention relates to a pharmaceutical dosage form wherein the dosage form is in a powder form and is contained in a pharmaceutically acceptable capsule. The present invention is also directed toward methods of making the dosage form, methods of using the dosage form, and kits comprising the dosage form.
    Type: Grant
    Filed: May 26, 2006
    Date of Patent: March 4, 2014
    Assignee: Teva Women's Health, Inc.
    Inventors: Salah U. Ahmed, Charles E. Diliberti, Chandra Vattikonda, Sudhir R. Gorukanti, Sanjeev K. Gupta
  • Methods of hormonal treatment utilizing ascending-dose extended cycle regimens
    Patent number: 8450299
    Abstract: The present invention provides ascending-dose extended cycle regimens in which a female is administered an estrogen and a progestin for a period of greater than 30 or 31 consecutive days, optionally followed by a hormone-free period or by a period of administration of estrogen. The disclosed regimens can be administered to a female to provide contraceptive and non-contraceptive benefits.
    Type: Grant
    Filed: June 8, 2012
    Date of Patent: May 28, 2013
    Assignee: Teva Womans's Health, Inc.
    Inventors: Charles E. Diliberti, Kathleen Z. Reape, Lance J. Bronnenkant
  • Methods of hormonal treatment utilizing ascending-dose extended cycle regimens
    Patent number: 8415332
    Abstract: The present invention provides ascending-dose extended cycle regimens in which a female is administered an estrogen and a progestin for a period of greater than 30 or 31 consecutive days, optionally followed by a hormone-free period or by a period of administration of estrogen. The disclosed regimens can be administered to a female to provide contraceptive and non-contraceptive benefits.
    Type: Grant
    Filed: August 17, 2007
    Date of Patent: April 9, 2013
    Assignee: Teva Woman's Health, Inc.
    Inventors: Charles E. Diliberti, Kathleen Z. Reape, Lance J. Bronnenkant
  • Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens
    Publication number: 20120252767
    Abstract: The present invention provides ascending-dose extended cycle regimens in which a female is administered an estrogen and a progestin for a period of greater than 30 or 31 consecutive days, optionally followed by a hormone-free period or by a period of administration of estrogen. The disclosed regimens can be administered to a female to provide contraceptive and non-contraceptive benefits.
    Type: Application
    Filed: June 8, 2012
    Publication date: October 4, 2012
    Applicant: Teva Women's Health, Inc.
    Inventors: Charles E. Diliberti, Kathleen Z. Reape, Lance J. Bronnenkant
  • METHODS OF REDUCING SYMPTOMS IN SUBJECTS USING SINGLE DOSAGE FORMS WITH TAPERING RELEASE RATES
    Publication number: 20110274740
    Abstract: The present invention is directed to methods of reducing symptoms associated with an abrupt reduction in an endogenous or exogenous chemical in subjects, the methods comprising: (a) administering to the subject a single dosage form comprising an active agent, wherein the release rate of the active agent from the single dosage form tapers throughout the administration; and (b) removing the single dosage form from the subjects after the release rate of the active agent is at or below a terminal symptom threshold level.
    Type: Application
    Filed: May 5, 2011
    Publication date: November 10, 2011
    Inventors: Charles E. DiLiberti, Anu Mahashabde
  • Methods for comparing the immunogenicity of products and uses thereof
    Patent number: 7833724
    Abstract: The present invention relates to methods of determining the immunogenic potential of a test product by comparing the immunogenic profile or fingerprint of the test product to the immunogenic profile or fingerprint of a reference product.
    Type: Grant
    Filed: March 20, 2007
    Date of Patent: November 16, 2010
    Assignee: Teva Women's Health, Inc.
    Inventors: Charles E. DiLiberti, Alan Liss
  • Regimens for Treatment of Conditions Related to Estrogen Deficiency
    Publication number: 20090247493
    Abstract: The present invention relates to methods of stimulating estrogen production that can be used to treat peri-menopausal or estrogen deficiency conditions utilizing regimens involving administration of estrogen and progestin, followed by a hormone-free period.
    Type: Application
    Filed: January 29, 2007
    Publication date: October 1, 2009
    Applicant: Duramed Pharmaceuticals, Inc.
    Inventors: Charles E. Diliberti, Kathleen Z. Reape
  • Dosage Regimens and Pharmaceutical Compositions and Packages for Emergency Contraception
    Publication number: 20090170823
    Abstract: The present invention is directed to dosage regimens for emergency contraception using nonsteroidal progestins and pharmaceutical compositions and packages thereof. Such regimens are useful for females in need of emergency contraception.
    Type: Application
    Filed: December 19, 2008
    Publication date: July 2, 2009
    Applicant: Duramed Pharmaceuticals, Inc.
    Inventor: Charles E. DILIBERTI
  • Methods of hormonal treatment utilizing ascending-dose extended cycle regimens
    Publication number: 20080125402
    Abstract: The present invention provides ascending-dose extended cycle regimens in which a female is administered an estrogen and a progestin for a period of greater than 30 or 31 consecutive days, optionally followed by a hormone-free period or by a period of administration of estrogen. The disclosed regimens can be administered to a female to provide contraceptive and non-contraceptive benefits.
    Type: Application
    Filed: August 17, 2007
    Publication date: May 29, 2008
    Applicant: Duramed Pharmaceuticals, Inc.
    Inventors: Charles E. Diliberti, Kathleen Z. Reape, Lance J. Bronnenkant